Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

The novel CETP inhibitor, once tested for the now-defunct pathway of HDL raising, reduces LDL as well as Lp(a).

Individuals assigned male at birth who were pushed to change their identity had more inflammation and higher blood pressure.

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

With both new and revised measures, the document’s authors aim to provide clinicians usable advice in a digestible format.

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.

Telling patients how many extra days they’ll be free from an event can help with shared decision-making, experts say.

The findings underscore the need to treat heart failure with urgency and double down on clinician education, one expert says.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.